Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amylyx Pharmaceuticals, Inc. - Common Stock
(NQ:
AMLX
)
4.410
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amylyx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Amylyx (AMLX) Stock Spikes 13% as FDA Resumes Discussion of ALS Drug
July 05, 2022
A new wrinkle in the story of Amylyx Pharmaceuticals' ongoing battle against ALS bodes well for patients, and for AMLX stock holders.
Via
InvestorPlace
Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session
July 05, 2022
Gainers Ra Medical Systems, Inc. (NASDAQ: RMED) shares jumped 69.6% to $0.5240 after the company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter.
Via
Benzinga
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
June 28, 2022
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before.
Via
Investor's Business Daily
Here's How Citi Views Amylyx Pharma
June 14, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Amylyx Pharma
June 14, 2022
Within the last quarter, Amylyx Pharma (NASDAQ:AMLX) has observed the following analyst ratings:
Via
Benzinga
Why Stealth BioTherapeutics Shares Are Surging Today?
June 08, 2022
Via
Benzinga
82 Biggest Movers From Yesterday
June 15, 2022
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.
Via
Benzinga
Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September
June 13, 2022
The Canadian government has given its approval to AMX0035, a new drug from Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc.
Via
Benzinga
Expert Ratings For Amylyx Pharmaceuticals
April 01, 2022
Within the last quarter, Amylyx Pharmaceuticals (NASDAQ:AMLX) has observed the following analyst ratings:
Via
Benzinga
FDA Panel Votes Down For Amylyx's ALS Drug, Further Fading Its Hope For Regulatory Success
March 31, 2022
An advisory committee of the
Via
Benzinga
Amylyx Pharma Stock Hinges On This FDA Action — Here's What To Know
March 30, 2022
Amylyx is facing an FDA advisory committee Wednesday that will vote on its ALS drug.
Via
Investor's Business Daily
83 Biggest Movers From Yesterday
June 09, 2022
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...
Via
Benzinga
69 Biggest Movers From Friday
June 06, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...
Via
Benzinga
Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher
June 03, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 300 points on Friday.
Via
Benzinga
Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate
June 03, 2022
The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals (NASDAQ: AMLX) for its lead drug candidate AMX0035...
Via
Benzinga
Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning
June 03, 2022
Novavax (NVAX) stock is falling on Friday after the FDA requested a heart inflammation warning for the company's Covid-19 vaccine.
Via
InvestorPlace
Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump
June 03, 2022
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday.
Via
Benzinga
40 Stocks Moving In Friday's Mid-Day Session
June 03, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Via
Benzinga
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today?
June 03, 2022
Amylyx Pharmaceuticals (AMLX) stock is rising higher on Friday following an update from the U.S. Food and Drug Administration (FDA).
Via
InvestorPlace
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May
June 03, 2022
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday.
Via
Benzinga
Former Red-Hot IPO Amylyx Soars On New Hopes For Its ALS Drug
June 03, 2022
The FDA pushed its review date for Amylyx Pharmaceuticals' controversial ALS treatment on Friday, and the biotech stock skyrocketed.
Via
Investor's Business Daily
Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today
June 03, 2022
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May 31, 2022
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022
May 25, 2022
Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of...
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
92 Biggest Movers From Friday
May 09, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...
Via
Benzinga
Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest
April 01, 2022
One analyst says Reata only has a 50% chance in a neurodegenerative disease.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022
April 01, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
March 31, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
March 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.